Phathom Pharmaceuticals (PHAT) Stock Statistics & Valuation Metrics

Phathom Pharmaceuticals has a market cap or net worth of $840.78M. The enterprise value is $713.52M.

Phathom Pharmaceuticals has 78,798,710 shares outstanding. The number of shares has decreased by -2.65% in one year.

Phathom Pharmaceuticals’s return on equity (ROE) is 0.50 and return on invested capital (ROIC) is -125.23%.

The current PE Ratio of Phathom Pharmaceuticals is ―. Phathom Pharmaceuticals’s PEG ratio is 0.13.

In the last 12 months, Phathom Pharmaceuticals had revenue of 175.11M and earned -221.25M in profits. Earnings per share was -3.03.

In the last 12 months, operating cash flow was -166.78M and capital expenditures 0.00, giving a free cash flow of -166.68M billion.

Phathom Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Phathom Pharmaceuticals upcoming earnings date is May 12, 2026, Before Open (Confirmed).

Phathom Pharmaceuticals as a current ratio of 1.73, with Debt / Equity ratio of -0.62%

In the past 12 months, Phathom Pharmaceuticals has paid 0.00 in taxes.

Phathom Pharmaceuticals EV to EBITDA ratio is -7.10, with an EV/FCF ratio of -6.49.

Phathom Pharmaceuticals has $129.97M in cash and marketable securities with $2.71M in debt, giving a net cash position of $127.26M billion.

Gross margin is 87.09%, with operating margin of -91.36%, and net profit margin of -126.35%.

The average price target for Phathom Pharmaceuticals is $25.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy